223 related articles for article (PubMed ID: 31060912)
21. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
22. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
23. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
[TBL] [Abstract][Full Text] [Related]
24. [Relation of B7-H3 molecule expression in multiple myeloma with poor prognosis and bone destruction].
Zhao DD; Lin L; Ge Q; Li ZY; He XP; Xu KL; Lu J; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):637-42. PubMed ID: 23815913
[TBL] [Abstract][Full Text] [Related]
25. The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer.
Jiang B; Zhang T; Liu F; Sun Z; Shi H; Hua D; Yang C
Oncotarget; 2016 May; 7(22):31755-71. PubMed ID: 27145365
[TBL] [Abstract][Full Text] [Related]
26. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
Front Oncol; 2021; 11():659662. PubMed ID: 34868903
[TBL] [Abstract][Full Text] [Related]
27. Molecular imaging of T cell co-regulator factor B7-H3 with
Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer.
Shao X; Zhan S; Quan Q; Shen Y; Chen S; Zhang X; Li R; Liu M; Cao L
Int Immunopharmacol; 2022 Sep; 110():108988. PubMed ID: 35777267
[TBL] [Abstract][Full Text] [Related]
29. B7-H3 targeted antibody-based immunotherapy of malignant diseases.
Michelakos T; Kontos F; Barakat O; Maggs L; Schwab JH; Ferrone CR; Ferrone S
Expert Opin Biol Ther; 2021 May; 21(5):587-602. PubMed ID: 33301369
[No Abstract] [Full Text] [Related]
30. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 Expression in Breast Cancer and Brain Metastasis.
Joshi V; Beecher K; Lim M; Stacey A; Feng Y; Jat PS; Duijf PHG; Simpson PT; Lakhani SR; McCart Reed AE
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612786
[TBL] [Abstract][Full Text] [Related]
32. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
33. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
[TBL] [Abstract][Full Text] [Related]
34. Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients.
Chen L; Xie Q; Wang Z; Shi L; Wu C; Jiang J
Oncotarget; 2016 Nov; 7(47):77237-77243. PubMed ID: 27764786
[TBL] [Abstract][Full Text] [Related]
35. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
[TBL] [Abstract][Full Text] [Related]
36. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
[TBL] [Abstract][Full Text] [Related]
37. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
38. Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblasts.
Xu L; Zhang G; Zhou Y; Chen Y; Xu W; Wu S; Zhang X
Immunobiology; 2011 Dec; 216(12):1311-7. PubMed ID: 21893365
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
40. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]